Univariate analysis of prognostic factors for survival.
Variables | PFS | OS | ||||
---|---|---|---|---|---|---|
HR | 95% CI | HR | 95% CI | |||
Age, ≥65 vs. <65 | 0.52 | 0.06–4.38 | 0.549 | 2.74 | 0.36–21.03 | 0.332 |
EBV, positive vs. negative | 0.28 | 0.03–2.72 | 0.270 | 0.54 | 0.05–5.95 | 0.613 |
ECOG, 0 or 1 vs. 2 | 2.31 | 0.43–12.54 | 0.331 | 18.81 | 1.72–206.00 | 0.016 |
Prior ASCT, yes vs. no | 0.56 | 0.10–3.03 | 0.505 | 0.56 | 0.06–5.55 | 0.622 |
Pembrolizumab vs. nivolumab | 0.58 | 0.11–3.18 | 0.530 | 0.53 | 0.05–5.19 | 0.609 |
Abbreviations: AASCT, autologous hematopoietic stem cell transplantation; CI, confidence interval; EBV, Epstein-Barr virus; ECOG, eastern cooperative oncology group; HR, hazard ratio; OS, overall survival; PFS, progression free survival.